Literature DB >> 27267515

FDA Approves Drug Combo for Kidney Cancer.

.   

Abstract

The FDA has approved the combination of lenvatinib and everolimus to treat advanced or metastatic renal cell carcinoma. The approval marks the first time that tyrosine kinase and mTOR inhibitors have been combined successfully as second-line treatment for renal cell carcinoma following prior VEGF-targeted therapy. ©2016 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27267515     DOI： 10.1158/2159-8290.CD-NB2016-067

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  5 in total

Review 1.  Lenvatinib in Management of Solid Tumors.

Authors:  Zhonglin Hao; Peng Wang
Journal:  Oncologist       Date:  2019-10-14

2.  The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo.

Authors:  Yun Zou; Jianfeng Wang; Xuejiao Leng; Jiwei Huang; Wei Xue; Jin Zhang; Yiran Huang
Journal:  Oncotarget       Date:  2017-03-28

Review 3.  RET signaling pathway and RET inhibitors in human cancer.

Authors:  Angelina T Regua; Mariana Najjar; Hui-Wen Lo
Journal:  Front Oncol       Date:  2022-07-25       Impact factor: 5.738

4.  Attenuation of everolimus-induced cytotoxicity by a protective autophagic pathway involving ERK activation in renal cell carcinoma cells.

Authors:  Yizhou Zeng; Xiaofang Tian; Quan Wang; Weiyang He; Jing Fan; Xin Gou
Journal:  Drug Des Devel Ther       Date:  2018-04-19       Impact factor: 4.162

5.  PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy.

Authors:  Wenfeng Fang; Yihua Huang; Weiguang Gu; Jiadi Gan; Wenjing Wang; Shiyue Zhang; Kai Wang; Jianhua Zhan; Yunpeng Yang; Yan Huang; Hongyun Zhao; Li Zhang
Journal:  Transl Lung Cancer Res       Date:  2020-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.